BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30327151)

  • 1. Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
    Deng H; Liu C; Zhang G; Wang X; Liu Y
    Pathol Res Pract; 2018 Dec; 214(12):2103-2105. PubMed ID: 30327151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].
    Ma XL; Jia RN; Han K; Zhang YX
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):578-584. PubMed ID: 38825903
    [No Abstract]   [Full Text] [Related]  

  • 4. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
    Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
    Schluckebier L; Caetano R; Garay OU; Montenegro GT; Custodio M; Aran V; Gil Ferreira C
    BMC Cancer; 2020 Sep; 20(1):875. PubMed ID: 32928143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
    Sakamoto T; Matsubara T; Takahama T; Yokoyama T; Nakamura A; Tokito T; Okamoto T; Akamatsu H; Oki M; Sato Y; Tobino K; Ikeda S; Mori M; Mimura C; Maeno K; Miura S; Harada T; Nishimura K; Hiraoka M; Kenmotsu H; Fujimoto J; Shimokawa M; Yamamoto N; Nakagawa K
    JAMA Netw Open; 2023 Dec; 6(12):e2347700. PubMed ID: 38100106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients.
    Zhang X; Jiang Y; Yu H; Xia H; Wang X
    World J Surg Oncol; 2020 Jul; 18(1):172. PubMed ID: 32677962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Small Cell Lung Cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.
    Paturu R; Lingaiah R; Kumari N; Singh S; Krishnani N; Srivastava S; Siddiqui SH; Nath A
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3467-3475. PubMed ID: 37898852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Receptor tyrosine kinase- fusions in paediatric spindle cell tumors].
    Brenner C; Sanders C; Vokuhl C
    Pathologie (Heidelb); 2023 Nov; 44(6):357-365. PubMed ID: 37819532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase gene rearrangements in epithelial malignancies.
    Shaw AT; Hsu PP; Awad MM; Engelman JA
    Nat Rev Cancer; 2013 Nov; 13(11):772-87. PubMed ID: 24132104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent chemistry on nanostructured substrates enables noninvasive quantification of gene rearrangements in circulating tumor cells.
    Dong J; Jan YJ; Cheng J; Zhang RY; Meng M; Smalley M; Chen PJ; Tang X; Tseng P; Bao L; Huang TY; Zhou D; Liu Y; Chai X; Zhang H; Zhou A; Agopian VG; Posadas EM; Shyue JJ; Jonas SJ; Weiss PS; Li M; Zheng G; Yu HH; Zhao M; Tseng HR; Zhu Y
    Sci Adv; 2019 Jul; 5(7):eaav9186. PubMed ID: 31392269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.
    Chang X; Liu Z; Man S; Roys A; Li Z; Zuo D; Wu Y
    RSC Adv; 2019 Jun; 9(31):17921-17932. PubMed ID: 35520562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.
    Khoo C; Rogers TM; Fellowes A; Bell A; Fox S
    Transl Lung Cancer Res; 2015 Apr; 4(2):126-41. PubMed ID: 25870795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
    Odintsov I; Sholl LM
    Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of ROS1 mutation with cancer immunity and its impact on the efficacy of pan-cancer immunotherapy.
    Li Y; Zhao H; Huang J; Yan H; Zhao B
    J Transl Med; 2024 Apr; 22(1):403. PubMed ID: 38689327
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutational landscape and predictors of survival in head and neck mucosal melanoma.
    Lehrich BM; Abiri A; Nguyen TV; Bitner BF; Tong CCL; Kuan EC
    Int Forum Allergy Rhinol; 2024 Apr; 14(4):858-861. PubMed ID: 37676479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.
    Wan Y; Liu B; Lei H; Zhang B; Wang Y; Huang H; Chen S; Feng Y; Zhu L; Gu Y; Zhang Q; Ma H; Zheng SY
    Ann Oncol; 2018 Dec; 29(12):2379-2383. PubMed ID: 30339193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting
    Sehgal K; Patell R; Rangachari D; Costa DB
    Transl Cancer Res; 2018 Aug; 7(Suppl 7):S779-S786. PubMed ID: 30327756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.